State Street Corp Has $35.36 Million Holdings in BioLife Solutions, Inc. (NASDAQ:BLFS)

State Street Corp raised its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 7.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 1,412,316 shares of the medical equipment provider's stock after acquiring an additional 95,788 shares during the period. State Street Corp owned 3.04% of BioLife Solutions worth $35,364,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Raymond James & Associates acquired a new stake in shares of BioLife Solutions in the second quarter worth approximately $2,876,000. Louisiana State Employees Retirement System grew its holdings in BioLife Solutions by 4.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 18,300 shares of the medical equipment provider's stock valued at $392,000 after purchasing an additional 700 shares in the last quarter. Calamos Advisors LLC purchased a new stake in BioLife Solutions during the 2nd quarter worth $1,227,000. Bank of New York Mellon Corp lifted its holdings in BioLife Solutions by 3.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 275,570 shares of the medical equipment provider's stock worth $5,905,000 after buying an additional 8,216 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in BioLife Solutions by 2.2% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 134,077 shares of the medical equipment provider's stock valued at $2,873,000 after buying an additional 2,874 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company's stock.

BioLife Solutions Price Performance

BLFS stock traded up $1.28 during trading hours on Friday, hitting $27.39. 1,077,464 shares of the stock traded hands, compared to its average volume of 386,862. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The stock has a 50-day simple moving average of $24.86 and a 200 day simple moving average of $23.68. BioLife Solutions, Inc. has a one year low of $14.50 and a one year high of $28.88. The company has a market cap of $1.27 billion, a P/E ratio of -25.84 and a beta of 1.91.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BLFS. TD Cowen upped their target price on BioLife Solutions from $28.00 to $31.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Craig Hallum lifted their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. HC Wainwright cut their price target on BioLife Solutions from $29.00 to $27.00 and set a "buy" rating on the stock in a report on Monday, November 18th. Benchmark reissued a "buy" rating and set a $30.00 price target on shares of BioLife Solutions in a report on Thursday. Finally, KeyCorp increased their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a report on Friday, December 13th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to data from MarketBeat, BioLife Solutions currently has an average rating of "Moderate Buy" and a consensus price target of $29.00.

Insider Buying and Selling

In other BioLife Solutions news, EVP Aby J. Mathew sold 10,000 shares of the company's stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $23.28, for a total transaction of $232,800.00. Following the completion of the sale, the executive vice president now directly owns 317,716 shares of the company's stock, valued at approximately $7,396,428.48. This represents a 3.05 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders sold 64,259 shares of company stock worth $1,424,708. Corporate insiders own 2.20% of the company's stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.